Literature DB >> 17521781

Single dose of SA 14-14-2 vaccine provides long-term protection against Japanese encephalitis: a case-control study in Nepalese children 5 years after immunization. drjbtandan@yahoo.com.

J B Tandan1, Heechoul Ohrr, Young Mo Sohn, Sutee Yoksan, Min Ji, Chung Mo Nam, Scott B Halstead.   

Abstract

In July 1999, a single dose of live-attenuated SA 14-14-2 Japanese encephalitis (JE) vaccine was administered to children living in the Bardiya, Banke and Kailali districts of Nepal. In 2004, the original vaccinated population experienced a fifth seasonal exposure to JE. We performed a case-control study comparing the prevalence of the administration of vaccine in patients with JE hospitalized in the Bardiya and Bheri Zonal hospitals and in age-sex matched controls resident in the Bardiya district. Among the 219 village controls, 114 had been vaccinated (52.1%) while only one of 20 JE cases had received live-attenuated JE vaccine. Five years after administration of a single dose, SA 14-14-2 provided a protective efficacy of 96.2% (CI 73.1-99.9%).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17521781     DOI: 10.1016/j.vaccine.2007.04.052

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  38 in total

Review 1.  Immunogenicity and safety of currently available Japanese encephalitis vaccines: a systematic review.

Authors:  Xing Li; Shu-Juan Ma; Xie Liu; Li-Na Jiang; Jun-Hua Zhou; Yi-Quan Xiong; Hong Ding; Qing Chen
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  A novel low-cost approach to estimate the incidence of Japanese encephalitis in the catchment area of three hospitals in Bangladesh.

Authors:  Repon C Paul; Mahmudur Rahman; Emily S Gurley; M Jahangir Hossain; Serguei Diorditsa; Asm Mainul Hasan; Sultana S Banu; Asm Alamgir; Muhammad Aziz Rahman; Hardeep Sandhu; Marc Fischer; Stephen P Luby
Journal:  Am J Trop Med Hyg       Date:  2011-08       Impact factor: 2.345

3.  Genetic and phenotypic properties of vero cell-adapted Japanese encephalitis virus SA14-14-2 vaccine strain variants and a recombinant clone, which demonstrates attenuation and immunogenicity in mice.

Authors:  Gregory D Gromowski; Cai-Yen Firestone; José Bustos-Arriaga; Stephen S Whitehead
Journal:  Am J Trop Med Hyg       Date:  2014-10-13       Impact factor: 2.345

Review 4.  Use of the live attenuated Japanese Encephalitis vaccine SA 14-14-2 in children: A review of safety and tolerability studies.

Authors:  Amy Sarah Ginsburg; Ankita Meghani; Scott B Halstead; Mansour Yaich
Journal:  Hum Vaccin Immunother       Date:  2017-08-25       Impact factor: 3.452

5.  Genetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in Mice.

Authors:  Gregory D Gromowski; Cai-Yen Firestone; Stephen S Whitehead
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

6.  Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.

Authors:  Peter E Nasveld; Joanne Marjason; Sonya Bennett; John Aaskov; Suzanne Elliott; Karen McCarthy; Niranjan Kanesa-Thasan; Emmanuel Feroldi; Mark Reid
Journal:  Hum Vaccin       Date:  2010-11-01

7.  Dengue virus and Japanese encephalitis virus epidemiological shifts in Nepal: a case of opposing trends.

Authors:  Shyam P Dumre; Geeta Shakya; Kesara Na-Bangchang; Veerachai Eursitthichai; Hans Rudi Grams; Senendra R Upreti; Prakash Ghimire; Khagendra KC; Ananda Nisalak; Robert V Gibbons; Stefan Fernandez
Journal:  Am J Trop Med Hyg       Date:  2013-02-18       Impact factor: 2.345

8.  Immunogenicity of a live-attenuated Japanese encephalitis vaccine in children and adolescents after hematopoietic stem cell transplantation.

Authors:  S Pakakasama; S Wattanatitan; C Techasaensiri; S Yoksan; S Sirireung; S Hongeng
Journal:  Bone Marrow Transplant       Date:  2014-07-21       Impact factor: 5.483

9.  Estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal.

Authors:  Shyam Raj Upreti; Kristen B Janusz; W William Schluter; Ram Padarath Bichha; Geeta Shakya; Brad J Biggerstaff; Murari Man Shrestha; Tika Ram Sedai; Marc Fischer; Robert V Gibbons; Sanjaya K Shrestha; Susan L Hills
Journal:  Am J Trop Med Hyg       Date:  2013-01-28       Impact factor: 2.345

10.  Past, present, and future of Japanese encephalitis.

Authors:  Susan L Hills; Deborah C Phillips
Journal:  Emerg Infect Dis       Date:  2009-08       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.